【24h】

Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer

机译:切除非小细胞肺癌化疗的模式和预测因素

获取原文
获取外文期刊封面目录资料

摘要

Chemotherapy combined with surgical resection improves survival in patients with stage II to IIIA non-small cell lung cancer (NSCLC) and may benefit selected patients with stage IB disease. We sought to evaluate chemotherapy use in resected stage IB to IIIA NSCLC over time and to identify predictors of perioperative chemotherapy administration.MethodsPatients with resected stage IB to IIIA NSCLC were identified from the National Cancer Data Base (2002 to 2011). Administration of chemotherapy was assessed over time. Hierarchical regression models were developed to assess patient, hospital, and tumor-level characteristics predicting perioperative chemotherapy administration.ResultsIn 55,016 stage IB patients, chemotherapy use significantly increased between 2002 and 2011 from 5.3% to 15.1% (p < 0.001). In 57,033 patients with stage II to IIIA disease, perioperative chemotherapy administration also significantly increased from 29.3% to 58.4% (p < 0.001). Multivariable analyses demonstrated stage IB and II to IIIA patients were less likely to receive chemotherapy if they were older, treated at an academic center (vs community), had more comorbidities, or had lower-grade tumors (all p < 0.05). Stage IB patients with tumors sized 4 cm or larger were more likely to receive chemotherapy (odds ratio, 3.16; 95% confidence interval, 2.73 to 3.65) than those with tumors smaller than 4 cm. Compared with stage IIA patients, stage IIB patients were no more likely to receive perioperative chemotherapy (odds ratio, 1.06; 95% confidence interval, 0.96 to 1.17), whereas stage IIIA patients received chemotherapy significantly more often (odds ratio, 2.82; 95% confidence interval, 2.55 to 3.11).ConclusionsThe use of chemotherapy has significantly increased in patients with resected stage IB to IIIA NSCLC. Although clinicians have increasingly adopted evidence-based recommendations, significant treatment gaps persist and represent areas for quality improvement.
机译:化学疗法与手术切除相结合可提高II至IIIA期非小细胞肺癌(NSCLC)患者的生存率,并可能使部分IB期疾病患者受益。我们试图评估随着时间推移在IB期至IIIA期NSCLC化疗的使用情况,并确定围手术期化疗的预测因素。随着时间的推移,对化疗的给药进行了评估。结果开发了分层回归模型来评估患者,医院和肿瘤水平特征,以预测围手术期化疗的结果。结果在2002年至2011年之间的55,016 IB期患者中,化学疗法的使用从5.3%显着增加到15.1%(p <0.001) 。在57033名II至IIIA期患者中,围手术期化疗的使用率也从29.3%上升至58.4%(p <0.001)。多变量分析表明,如果年龄较大,在学术中心(相对于社区)进行治疗,合并症较多或肿瘤较轻,则IB和II至IIIA期患者接受化疗的可能性较小(所有p <0.05)。与肿瘤小于4 cm的IB期患者相比,肿瘤大于或等于4 cm的患者更可能接受化疗(几率为3.16; 95%置信区间为2.73至3.65)。与IIA期患者相比,IIB期患者不太可能接受围手术期化疗(赔率,1.06; 95%置信区间,0.96至1.17),而IIIA期患者接受化疗的频率更高(赔率,2.82; 95%置信区间为2.55至3.11)。结论在IB至IIIA期NSCLC切除患者中,化疗的使用显着增加。尽管临床医生越来越多地采用基于证据的建议,但仍然存在重大的治疗差距,并代表了质量改进的领域。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号